Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in AJR Am J Roentgenol Retrieve available abstracts of 46 articles: HTML format

Single Articles

September 2025
1. CASTAGNOLI F
   Turning Anatomy Into Action: Everything You Wanted to Know About Hepatocellular Carcinoma-and Need to Know for Your Next Report.
   AJR Am J Roentgenol. 2025 Sep 3. doi: 10.2214/AJR.25.33791.
   PubMed    
   
   
   August 2025
2. LUDWIG DR
   Anatomic Considerations in Hepatocellular Carcinoma: How to Improve Reporting and Facilitate Treatment Selection.
   AJR Am J Roentgenol. 2025 Aug 27. doi: 10.2214/AJR.25.33753.
   PubMed    
   
   
   
3. CHIU SH, Kesselman A, Delitto DJ, Dhanasekaran R, et al
   Hepatocellular Carcinoma: A Practical Anatomy-Based Guide for Staging and Treatment Planning, From the AJR Special Series on Critical Anatomy.
   AJR Am J Roentgenol. 2025 Aug 20. doi: 10.2214/AJR.25.33389.
   PubMed     Abstract available
   
   
   July 2025
4. CROCETTI L, Gaba RC, Ninalowo H, Yamamoto A, et al
   The Global Reading Room: Managing Hematemesis and Encephalopathy in a Patient With Portal Hypertension.
   AJR Am J Roentgenol. 2025 Jul 9. doi: 10.2214/AJR.25.33472.
   PubMed    
   
   
   June 2025
5. DIETRICH CF
   Current Challenges of the Expanding Role of Contrast-Enhanced Ultrasound in Hepatocellular Carcinoma Diagnosis Using LI-RADS.
   AJR Am J Roentgenol. 2025 Jun 4. doi: 10.2214/AJR.25.33329.
   PubMed    
   
   
   May 2025
6. LI L, Burgio MD, Fetzer DT, Ferraioli G, et al
   Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Diagnosis-AJR Expert Panel Narrative Review.
   AJR Am J Roentgenol. 2025 May 28. doi: 10.2214/AJR.25.32813.
   PubMed     Abstract available
   
   
   
7. GABRIEL H
   The Urgent Need for Standardizing Ultrasound Quantification of Hepatic Steatosis.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33161.
   PubMed    
   
   
   
8. HORII SC
   Determination of the Hepatic Attenuation Coefficient: Importance of a Scanning Protocol That Accounts for the Ultrasound Machine and Depth of the Hepatic ROI.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33148.
   PubMed    
   
   
   
9. KELLER EJ
   If You Can Superselect a Hepatic Artery, You Can Learn Prompt Engineering.
   AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33212.
   PubMed    
   
   
   
10. BURGIO MD
    Prognostic Value of LI-RADS CT/MRI Radiation Treatment Response Assessment Version 2024 in Hepatocellular Carcinoma Treated with Y-90 Radioembolization.
    AJR Am J Roentgenol. 2025 May 14. doi: 10.2214/AJR.25.33219.
    PubMed    
    
    
    
11. BLUTH EI
    The Use of Ultrasound Attenuation Measurements to Evaluate Hepatic Steatosis.
    AJR Am J Roentgenol. 2025 May 7. doi: 10.2214/AJR.25.33154.
    PubMed    
    
    
    
12. FERRAIOLI G, Roccarina D, Barr RG
    Reply to "The Use of Ultrasound Attenuation Measurements to Evaluate Hepatic Steatosis".
    AJR Am J Roentgenol. 2025 May 7. doi: 10.2214/AJR.25.33189.
    PubMed    
    
    
    April 2025
13. CANNELLA R
    Beyond the AJR: Insights on Hepatocellular Carcinoma Diagnosis From the Updated EASL Clinical Practice Guidelines.
    AJR Am J Roentgenol. 2025 Apr 30. doi: 10.2214/AJR.25.33112.
    PubMed    
    
    
    
14. CHIU SH, Kesselman A, Yoon L, Kamaya A, et al
    LI-RADS CT/MRI Radiation Treatment Response Algorithm Version 2024: Category Redistribution and Short-Term Outcomes in Patients Undergoing Y-90 Radioembolization for HCC.
    AJR Am J Roentgenol. 2025 Apr 30. doi: 10.2214/AJR.25.32745.
    PubMed     Abstract available
    
    
    
15. HONG CW, Yang Y, Remick I, Su P, et al
    Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study.
    AJR Am J Roentgenol. 2025 Apr 16. doi: 10.2214/AJR.25.32888.
    PubMed    
    
    
    
16. FERRAIOLI G, Roccarina D, Barr RG
    Attenuation Coefficient for Hepatic Steatosis Using a Single Ultrasound System: Associations of Measurement Parameters With Interoperator Agreement and Diagnostic Performance.
    AJR Am J Roentgenol. 2025 Apr 16. doi: 10.2214/AJR.25.32746.
    PubMed     Abstract available
    
    
    March 2025
17. MARKS RM
    Beyond the AJR: How Does Noncontrast MRI Compare With Ultrasound For Hepatocellular Carcinoma Surveillance in a Prospective Randomized Trial?
    AJR Am J Roentgenol. 2025 Mar 5. doi: 10.2214/AJR.25.32893.
    PubMed    
    
    
    February 2025
18. ZHOU S, Zhou G, Shen Y, Xia T, et al
    LI-RADS Nonradiation Treatment Response Algorithm Version 2024: Diagnostic Performance and Impact of Ancillary Features.
    AJR Am J Roentgenol. 2025;224:e2432035.
    PubMed     Abstract available
    
    
    January 2025
19. LOCKHART ME
    Editorial Comment: Updated LI-RADS Ultrasound Surveillance Version 2024 Detects More Hepatocellular Carcinomas Than Version 2017 in Patients With Cirrhosis.
    AJR Am J Roentgenol. 2025 Jan 29. doi: 10.2214/AJR.25.32695.
    PubMed    
    
    
    
20. HEO S, Kim SY, Lee SJ, Lee SS, et al
    LI-RADS Ultrasound Surveillance Version 2024: Comparison With Version 2017 for Hepatocellular Carcinoma Detection and Risk Factors for Visualization Score C.
    AJR Am J Roentgenol. 2025 Jan 22. doi: 10.2214/AJR.24.32433.
    PubMed     Abstract available
    
    
    
21. MCGILLEN K
    Editorial Comment: LI-RADS Ultrasound Surveillance Version 2024 Results in Increased Sensitivity for Detecting Hepatocellular Carcinoma.
    AJR Am J Roentgenol. 2025 Jan 22. doi: 10.2214/AJR.25.32674.
    PubMed    
    
    
    October 2024
22. ZHANG HH, Tan XZ
    Dual-Energy CT of Intrahepatic Splenosis.
    AJR Am J Roentgenol. 2024 Oct 2. doi: 10.2214/AJR.24.31816.
    PubMed    
    
    
    September 2024
23. ZHANG LX, Burgio MD, Vilgrain V, Fang C, et al
    Quantitative Ultrasound and Ultrasound-Based Elastography for Chronic Liver Disease: Practical Guidance, From the AJR Special Series on Quantitative Imaging.
    AJR Am J Roentgenol. 2024 Sep 11. doi: 10.2214/AJR.24.31709.
    PubMed     Abstract available
    
    
    July 2024
24. DABIRI BE
    Editorial Comment: Ablation for Early-Stage Hepatocellular Carcinoma Results in Lower Costs Relative to Both Surgical Resection and Transplant.
    AJR Am J Roentgenol. 2024 Jul 17. doi: 10.2214/AJR.24.31657.
    PubMed    
    
    
    
25. CAO JJ, Shen L, Yoon L, Kamaya A, et al
    Differentiation of Hepatocellular Adenoma Subtypes and Focal Nodular Hyperplasia on Gadoxetate Disodium-Enhanced MRI: An Updated Diagnostic Algorithm.
    AJR Am J Roentgenol. 2024 Jul 17. doi: 10.2214/AJR.24.31628.
    PubMed    
    
    
    
26. KIERANS AS, Borhani AA
    Beyond the AJR: The Need for Studies Evaluating the Added Value of Abbreviated MRI for Hepatocellular Carcinoma Surveillance in Geographically Diverse Prospective Cohorts.
    AJR Am J Roentgenol. 2024 Jul 3. doi: 10.2214/AJR.24.31662.
    PubMed    
    
    
    June 2024
27. CHARALEL RA, Mushlin AI, Zheng X, Mao J, et al
    Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
    AJR Am J Roentgenol. 2024 Jun 20. doi: 10.2214/AJR.24.31272.
    PubMed     Abstract available
    
    
    May 2024
28. 
    Correction for "Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection".
    AJR Am J Roentgenol. 2024 May 29:1. doi: 10.2214/AJR.24.31469.
    PubMed    
    
    
    April 2024
29. CALLIADA F
    Editorial Comment: Multiparametric Ultrasound Assessment of Hepatic Fat Fraction in a Real-World Population.
    AJR Am J Roentgenol. 2024 Apr 3. doi: 10.2214/AJR.24.31226.
    PubMed    
    
    
    
30. FERRAIOLI G
    Editorial Comment: A Step Toward the Clinical Application of Quantitative Ultrasound in the Diagnosis of Steatotic Liver Disease.
    AJR Am J Roentgenol. 2024 Apr 3. doi: 10.2214/AJR.24.31215.
    PubMed    
    
    
    March 2024
31. KUBALE R, Schneider G, Lessenich CPN, Buecker A, et al
    Ultrasound-Derived Fat Fraction for Hepatic Steatosis Assessment: Prospective Study of Agreement With MRI PDFF and Sources of Variability in a Heterogeneous Population.
    AJR Am J Roentgenol. 2024 Mar 20. doi: 10.2214/AJR.23.30775.
    PubMed     Abstract available
    
    
    January 2024
32. SERAI SD, Franchi-Abella S, Syed AB, Tkach JA, et al
    MR and Ultrasound Elastography for Fibrosis Assessment in Children: Practical Implementation and Supporting Evidence-AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2024 Jan 3. doi: 10.2214/AJR.23.30506.
    PubMed     Abstract available
    
    
    
33. KIELAR A
    Editorial Comment: Radiologists' Roles and Opportunities in Alcohol-Associated Liver Disease.
    AJR Am J Roentgenol. 2024;222:e2330296.
    PubMed    
    
    
    
34. SQUIRES JH
    Editorial Comment: A Role for Assessing Liver Stiffness by Shear-Wave Elastography in Patients With Fontan Circulation.
    AJR Am J Roentgenol. 2024;222:e2330073.
    PubMed    
    
    
    
35. SHANBHOGUE K
    Editorial Comment: MR Elastography of the Liver-Practical Guidelines for Optimal Clinical Use.
    AJR Am J Roentgenol. 2024;222:e2329642.
    PubMed    
    
    
    
36. CHAVHAN GB, Kim JH, Squires JH, Toso S, et al
    The Global Reading Room: An Incidental Liver Lesion in a Teenager.
    AJR Am J Roentgenol. 2024;222:e2329350.
    PubMed    
    
    
    December 2023
37. KING KG
    Editorial Comment: Perfluorobutane Increases Sensitivity and Accuracy in Hepatocellular Carcinoma Diagnosis Compared With Purely Intravascular Contrast Agents.
    AJR Am J Roentgenol. 2023 Dec 6. doi: 10.2214/AJR.23.30601.
    PubMed    
    
    
    November 2023
38. KANG HJ, Lee JM, Yoon JH, Yoo J, et al
    Contrast-Enhanced Ultrasound With Perfluorobutane for Hepatocellular Carcinoma Diagnosis: Comparison of Imaging Phases and Diagnostic Criteria.
    AJR Am J Roentgenol. 2023 Nov 22. doi: 10.2214/AJR.23.30156.
    PubMed     Abstract available
    
    
    October 2023
39. ZHANG LX, Tang A
    Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Counterpoint-Hepatobiliary Contrast Agents Improve Detection and Characterization.
    AJR Am J Roentgenol. 2023 Oct 4. doi: 10.2214/AJR.23.30140.
    PubMed    
    
    
    
40. TAMANDL D, Schima W
    Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Point-Why Extracellular Contrast Agents Are Superior for This Task.
    AJR Am J Roentgenol. 2023 Oct 4. doi: 10.2214/AJR.23.30254.
    PubMed    
    
    
    
41. CAO JJ, Kwon DH, Ghaziani TT, Kwo P, et al
    Accuracy of Information Provided by ChatGPT Regarding Liver Cancer Surveillance and Diagnosis.
    AJR Am J Roentgenol. 2023;221:556-559.
    PubMed    
    
    
    September 2023
42. MAHESHWARI S, Gu CN, Caserta MP, Kezer CA, et al
    Imaging of Alcohol-Associated Liver Disease.
    AJR Am J Roentgenol. 2023 Sep 20. doi: 10.2214/AJR.23.29917.
    PubMed     Abstract available
    
    
    
43. LAN T, Wei B
    Proper Hepatic Artery Pseudoaneurysm Treated by Endovascular Stent.
    AJR Am J Roentgenol. 2023 Sep 13. doi: 10.2214/AJR.23.30088.
    PubMed    
    
    
    August 2023
44. BRAAT AJAT, Kim HC, Vogl TJ, White SB, et al
    The Global Reading Room: A Patient With Neuroendocrine Liver Metastases After Pancreaticoduodenectomy.
    AJR Am J Roentgenol. 2023 Aug 23. doi: 10.2214/AJR.23.30113.
    PubMed    
    
    
    June 2023
45. DEIPOLYI AR, Ward RC, Riaz A, Vogl TJ, et al
    Locoregional Therapies for Primary and Metastatic Breast Cancer: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2023 Jun 28. doi: 10.2214/AJR.23.29454.
    PubMed     Abstract available
    
    
    May 2023
46. YIN M, Ehman RL
    MR Elastography: Practical Questions, From the AJR Special Series on Imaging of Fibrosis.
    AJR Am J Roentgenol. 2023 May 10. doi: 10.2214/AJR.23.29437.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.